- Study Protocol
- Open Access
Rationale and study protocol for We-PAP: a randomized pilot/feasibility trial of a couples-based intervention to promote PAP adherence and sleep health compared to an educational control
Pilot and Feasibility Studies volume 8, Article number: 171 (2022)
Obstructive sleep apnea (OSA) is a serious health condition that affects approximately 30-50% of older adults and contributes to risk for cardiometabolic disorders and dementia. Despite the well-documented role of partners in treatment seeking and adherence to positive airway pressure (PAP), treatments for OSA have nearly exclusively focused on the patient and current treatments for OSA do not address co-existing sleep problems such as insomnia that are prevalent in both patients with OSA and their partners. Therefore, the goal of this study is to develop and test a novel couples-based sleep health intervention to promote adherence to PAP and improve sleep health of the couple.
We are conducting a two-arm, parallel group, single blind, randomized controlled pilot/feasibility trial to compare our novel couples-based sleep health intervention (We-PAP) to an information control group (IC). We-PAP is based on a transdiagnostic model and uses a dyadic approach including increasing effective partner support, communication skills, and couple-level goal-setting. We-PAP involves 3 sessions and delivered via telehealth in weekly sessions. The IC includes standardized patient educational materials. Both groups receive the usual follow-up with their medical team. The study involves assessments at pre-treatment, post-intervention (approximately 1 month after starting PAP and completing We-PAP sessions or IC) and 3 months after starting PAP. Our main outcomes are feasibility and acceptability ratings. Secondary outcomes include comparing We-PAP to IC for PAP adherence, sleep quality (self-report and objective) and cognitive measures.
We-PAP is the first couples-based transdiagnostic sleep health intervention for patients with OSA and their partners. Results of this study will be used to inform the design of a subsequent fully powered clinical trial. If successful, this intervention could significantly advance current clinical practice in the treatment of OSA and sleep health more comprehensively in older adults. Moreover, this intervention may be useful for improving sleep in other aging populations with multiple sleep and other health problems, including patients with chronic illnesses or those at risk for Alzheimer’s disease and their caregivers.
NCT04759157. Date of registration: February 8, 2021. URL of trial registry record.
Obstructive sleep apnea (OSA) is a major public health problem that affects 30% to 50% of older adults1 and is associated with significant morbidity and mortality. Older adults with OSA have a significantly increased risk for cardiovascular disease  and stroke [3, 4] and have five times the risk for Alzheimer’s disease (AD) and related dementias [5, 6]. The physiological consequences of OSA, including intermittent hypoxia and oxidative stress are key mechanisms that drive neurodegeneration and AD pathophysiology [7, 8]. Given that 61% of adults share a bed with a partner , the consequences of OSA, including fragmented sleep, reduced quality of life, and increased marital conflict, affect both the patient and partner [10, 11]. Further, given that sleep fragmentation is also mechanistically linked with increased risk for cognitive decline and is a symptom experienced by both the patient with OSA and their bedpartner , the public health consequences of OSA are far greater than just that experienced by the patient alone.
The first-line treatment for OSA, positive airway pressure (PAP), is highly effective at treating OSA symptoms in the patient and improving both patient and bedpartner sleep. There is a dose-response relationship between PAP adherence and improvements in both patient and bedpartner sleep , daytime sleepiness, and QOL, as well as reductions in OSA patients’ cardiometabolic and AD risk factors, including hypertension [14, 15]. PAP treatment may slow cognitive decline in patients with dementia . Unfortunately, however, up to 80% of patients are non-adherent [15, 17, 18]. Patterns of PAP use in the first 30 days strongly predict later adherence [19, 20] and reimbursement of this treatment hinges on documenting adherence at 30–90 days. Therefore, interventions focusing on early use among new PAP users are vital to treatment success and to promote patient and bedpartner health.
There is a strong scientific premise for targeting PAP adherence at the couple-level. First, a consistent body of evidence demonstrates that couples’ sleep is highly interdependent, meaning that sleep in one partner affects and is affected by the other partner’s sleep . In fact, a PAP clinical trial showed that treating OSA was associated with a 50% reduction in bedpartners’ nocturnal arousals . Second, bedpartner’s sleep disruption is a primary motivator for patients to seek OSA diagnosis. In contrast, 50% of OSA patients reported they would not use PAP if it disrupted their partners’ sleep . Third, evidence from other chronic illness populations (e.g., cancer, HIV, diabetes) shows that couples-based interventions  are effective at improving adherence, symptom management, and patient and partner health outcomes. Finally, partner support is critical to promote PAP adherence, whereas relationship conflict may reduce adherence [24, 25]. Our previous studies have shown that collaborative support (e.g., helping with the PAP machine) strongly predicted greater adherence, whereas pressure (e.g., nagging) to use CPAP  and relationship conflict predicted lower adherence .
Only one previous pilot investigation  examined use of a couples’ education and support intervention compared to patient-oriented education and usual care groups. Results demonstrated improvements in patient PAP adherence as well as moderate to large improvements in sleep quality and reductions in daytime sleepiness in patients and partners in the couples’ group; however, only 6 of 10 couples randomized to this condition completed the intervention, highlighting the challenge of having both couple members attend in-person sessions. Furthermore, this pilot study focused exclusively on enhancing PAP adherence as opposed to addressing sleep issues experienced by both members of the couple, which may have reduced partner motivation to participate. Collectively, these findings provide a strong theoretical rationale and preliminary empirical support for integrating the partner into PAP adherence interventions; however, new treatment approaches are needed to reduce couples’ burden and enhance treatment engagement.
Our proposed intervention is the first treatment for OSA that uses a couples-based treatment model to target PAP adherence, as well as the broader sleep health issues affecting both patient and partner. In doing so, we aim to address the limitations of prior studies by focusing on collaboration of the couple and addressing sleep health issues in both partner members, as opposed to exclusively focusing on the individual with OSA. Beyond OSA, older adults are at increased risk for poor sleep health, including insomnia/poor sleep quality, circadian disruptions (phase advances or irregular sleep/wake schedules), and irregular sleep-wake schedules, which can significantly increase risk for cardiometabolic disorders, cognitive decline, poor relationship functioning, and reduced QOL [27,28,29,30,31]. Further, OSA and insomnia commonly co-occur, with 22 to 55% having both conditions . Moreover, partners of individuals who snore are three times more likely to have insomnia as compared to those living with non-snorers . Finally, patients with insomnia have poorer PAP adherence , and partners’ sleep disturbances are associated with reduced PAP adherence . Recent studies have tested insomnia treatments in patients with OSA and demonstrate promising results [32, 34, 35]. Importantly, no existing treatments focus on improving sleep health in partners of OSA patients, who are also a high-risk group for sleep disturbances . Therefore, our intervention fills a critical gap by addressing sleep health in older adults with OSA and their partners, with the goal of improving PAP adherence, QOL, and the sleep and health of both partners.
Accordingly, the goal of this manuscript is the provide the theoretical framework, intervention details, assessments and analysis plan of the We-PAP intervention, a couples-based intervention aimed at improving PAP adherence and sleep health for both the patient and partner. This intervention aims to address barriers to couples-based treatment by focusing on collaboration for both partners’ sleep health and delivering a brief intervention via a convenient and user-friendly telehealth format.
Design and methods
Study design overview
The study flow diagram is listed in Fig. 1. This is a two-arm, parallel-group, single-blind, randomized controlled pilot trial to evaluate the feasibility and preliminary effectiveness of “We-PAP”, a novel, couples-based sleep health intervention for patients with OSA and their partners compared to an information control (IC). Participants include patients who are newly diagnosed with OSA and starting PAP therapy and their partners (n = 40 couples). After completing a pre-treatment baseline assessment, couples are randomly assigned to a 3-session online sleep health intervention (We-PAP) or to a patient-focused information control group (IC) arm. Patients and partners complete follow-up assessments at post-treatment (approximately 1 month after starting PAP) and 3 months after starting PAP treatment. Approval for this on-going study was provided by the University of Utah Institutional Review Board (IRB_000135927). The study is registered with ClinicalTrials.gov (NCT04759157, 2/13/2021).
We-PAP is based on the transdiagnostic sleep and circadian model (i.e., a treatment that addresses common components of multiple disorders rather than a single disorder) . This model uses the basic principles of sleep regulation (e.g., regulating sleep pressure and improving the regulation of the circadian system) as building blocks for improving sleep health for a variety of sleep conditions. In this study, we expanded this transdiagnostic framework to couples’ sleep health conceptualization, in that both partners’ sleep health as a “shared” experience. Our intervention contain three crosscutting themes, present in each session: education, dyadic coping and enhancing communication. Education includes education about sleep apnea, PAP treatment, and sleep health. Dyadic coping refers to the recognition that the illness (OSA) affects both members of the couple, which evokes a coping response in both members. Therefore, We-PAP helps OSA patients and partners conceptualize PAP adherence and both of their sleep health issues as a couple-level problem (i.e., a “we problem”). The enhancing communication theme focuses on promoting collaborative support within the couple and reducing conflict. Substantial research in couples shows that while a supportive partner is crucial for supporting an array of health behaviors, including diet, physical activity, sleep, and treatment adherence, a high conflict relationship is a primary source of stress, which can undermine health behaviors [11, 37,38,39].
Recruitment, screening, and consent
A total of 40 couples will be recruited from the University of Utah Health Sleep Centers. Patients who are undergoing testing (in-lab or home sleep testing) are provided a letter introducing the study and notifying them they may be contacted about the study. Study staff contact potential patients via phone and email to provide study information and if interested, conduct screening for study eligibility. After completing screening, couples schedule an online consent visit over a HIPAA-compliant video conference platform (Zoom) to review and sign the online consent form and arrange to complete the baseline assessment. We enhanced our recruitment of patients from diverse backgrounds by using flyers with pictures of patients from different ethnicities and recruiting patients from suburban sleep clinics that serve a more diverse patient population.
Inclusion criteria for the couple include (1) age 50–85 years; (2) mixed or same sex couples who are married or living with a romantic partner for at least 1 year; (3) Patient is PAP naïve or re-initiating PAP after (3 or more years; (4) able to read and write in English; (5) Able to access online, video-conference capabilities (Wi-Fi or cellular plan)
Exclusion criteria include (1) self-reported diagnosis of severe comorbid sleep disorders other than insomnia (e.g., moderate or severe RLS; REM Behavior Disorder, narcolepsy); (2) presence of severe medical and psychiatric disorders that would interfere with participation in treatment (schizophrenia, bipolar disorder, hemodialysis); (3) patient is using supplemental oxygen or adaptive servo-ventilation.
Inclusion criteria justifications
Our age criteria (age > 50) was selected because the focus of our project is on improving the treatment of OSA to promote healthy aging. We included both bed-sharing and non-bed sharing couples based on feedback from our preliminary focus groups. Provided reasons included that partners need more education and support in initiating and maintaining progress with PAP treatment regardless of whether they share a bed, as well as concerns about feasibility, given that many older adult couples with OSA choose to sleep apart. Patients who use supplemental oxygen or ASV are excluded due to the presence of additional comorbidities beyond OSA, such as cardiopulmonary disease or other hypoventilatory disorders that lead to more challenges in ensuring adequate optimization of PAP-based treatments.
Upon completion of the baseline assessment, couples are randomly assigned to either We-PAP or IC using the RedCAP randomization algorithm. The randomization table, developed by the statistician (BB), uses a 1:1 ratio of We-PAP to IC with equal strata for male and female patients using a random number generator. The study interventionist confirms with the study staff that the couple meet the eligibility criteria then contacts the couple via letter and email to notify them of their group assignment.
At baseline/pretreatment, couples complete questionnaires, 7 days of wrist actigraphy and daily sleep diaries (delivered either via text message or on paper), and a brief cognitive testing battery. Approximately 1 month after beginning PAP and upon completion of their intervention, couples complete a second set of questionnaires. Finally, at 3 months after starting PAP, couples complete questionnaires, 7 days of actigraphy and daily sleep diaries and a brief cognitive testing battery. PAP use data are collected via download using the corresponding cloud-based system. The 3-month time point was selected as the primary endpoint because this is consistent with Medicare criteria for continuing coverage for PAP treatment. The 1-month assessment is included to evaluate the early changes with PAP because early adherence and improvement in outcomes are associated with longer term adherence .
We-Pap was developed through an iterative process that included focus groups and a brief field trial (n = 4 couples) before beginning the RCT. This intervention is a novel, couples-focused PAP adherence and sleep health treatment that combines a transdiagnostic sleep and circadian framework with a dyadic (i.e., couples) perspective. Each couple assigned to the We-PAP intervention completes three online Zoom-hosted, sessions conducted weekly, utilizing structured PowerPoint slides. All sessions are structured, but interactive, and include the themes of sleep education, dyadic coping and communication. Each session has content geared at the patient, partner and the couple. A detailed list of session content is listed in Table 1.
Session 1 (75 min) focuses on assessment and the couples’ sleep, knowledge about OSA, and expectations for beginning PAP. The main content of the session reviews education about PAP treatment including overcoming early challenges to PAP treatment and how to effectively communicate and elicit partner support for troubleshooting.
Session 2 (60 min) focuses on sleep health and strategies to improve poor sleep (techniques based on Brief Behavioral Treatment for Insomnia; BBTI)  including improving sleep habits, reducing time in bed, stimulus control techniques, and setting a consistent rise time. Sleep diary data between Sessions 1 and 2 are reviewed.
Session 3 (60 min) begins by reviewing the patient’s PAP download, discussing each person’s sleep diaries and adjusting the sleep window, then discusses the role of stress and hyperarousal, both in general and specific to adjusting to PAP, including techniques for PAP desensitization and establishing a wind-down routine for the couple that incorporates PAP as the final step of the routine.
During each session, the interventionist reviews homework (if applicable), presents session content, engages the couple in discussion and planning and assigns homework for the next session (if applicable).
Information control (IC)
In this group, couples receive a packet of standardized patient educational materials about OSA and PAP published by the American Academy of Sleep Medicine on the website Sleepeducation.org. The purpose of this group is to compare our novel intervention to a standardized usual care comparator. This group is considered an enhanced usual care group, because they are receiving usual care in the sleep clinic plus standardized medical information provided by the research study . The interventionist will contact couples to notify them of their study assignment and then follow-up with them with a phone or email contact to ensure they have received the study materials. If the couple has questions about PAP, the interventionist refers couples to direct questions to their sleep medicine provider or durable medical equipment (DME) company.
Interventionist training, supervision, and fidelity monitoring
All We-Pap intervention sessions are recorded for training and fidelity monitoring. The interventionist delivering the We-PAP intervention content has a doctoral degree in clinical psychology and is currently participating in a Behavioral Sleep Medicine Fellowship program. Training included didactics, supervised telehealth patient sessions focused on CBTi at the University of Utah Sleep Wake Center, rehearsal of We-Pap sessions prior to the field trial, role-playing, review of pre-recorded session format provided by the lead investigators, in-person review and coaching of digitally recorded field trial sessions, and weekly supervision meetings. The interventionist is supervised by one of the lead investigators (WT). Fidelity is monitored via a structured checklist completed by the therapist at the end of each session and 10% of sessions will be rated for fidelity by one of the lead investigators (WT or KB). The checklist also includes an open-ended comments section, where the interventionist writes notes to review in weekly meetings with the supervisor.
Participants complete a brief demographic measure, including age, sex, race/ethnicity, marital status, education level, employment status, household income level, substance use, and bed-sharing.
OSA severity (AHI) will be extracted from medical records.
Feasibility and acceptability measures
Our primary outcomes assess feasibility of enrollment and retention including (1) our ability to meet recruitment goals (4 couples per month) and (2) percentage of participants completing all three intervention sessions. We also collect other quantitative ratings of feasibility and acceptability of the treatment including Likert scale ratings of ease of participation in the telehealth, and perceived benefits of the intervention and enjoyment of the sessions. Additionally, we collect qualitative data via open-ended questions about the format, feedback on the content, materials and general feedback and suggestions for improving the interventions. Success will be defined as meeting recruitment goals of our study (enrolling 100% of the planned sample) and retention of 85% of our participants in the intervention.
Secondary outcome measures
PAP adherence (main secondary outcome)–patient PAP adherence is recorded by the patient’s PAP machine and remotely downloaded. PAP adherence is measured continuously. The main time point for adherence is at 3 months. The average duration of use per night, percent of nights with use > 4 h, and nights skipped is recorded.
Objective sleep measures
Sleep is estimated using the Actiwatch Spectrum Plus (Philips Respironics, Murrysville, PA, USA). Actiwatches are configured with default settings using 30-s epochs. Rest intervals are manually set with assistance of a sleep diary (to indicate bedtimes and wake times). Using the Actiware software, we calculate total sleep time, sleep onset time, sleep offset time, sleep duration, sleep efficiency, sleep latency, wake after sleep onset, and sleep fragmentation index. The main measure of sleep quality is sleep efficiency.
Participants complete the Consensus Sleep Diary  to quantitatively assess dimensions of sleep that are important for a wide-range of clinical and research applications. Items include time the individual got into and out of bed, time the individual tried to go to sleep, duration to fall asleep, and frequency and total duration of awakenings, time of final awakening and sleep quality rating. Two additional items included in the diary assess whether partners shared a bed (yes/no) and the degree to which the couple worked together to use PAP (rated on a scale 1–5).
Sleep disturbance and sleep-related impairment
Participants complete the PROMIS sleep disturbance and sleep-related impairment adaptive measures  Scores are presented as t scores, with average of 50 and SD of 10. Scores > 60 are considered elevated. Self-reported sleep is measured using a standardized sleep diary and the PROMIS sleep disturbance questionnaire.
Other outcome measures
Participants complete the Couples Satisfaction Index (CSI-4)  to evaluate an individual’s self-reported degree of satisfaction, happiness, warmth and comfort, and reward with the relationship. The 4-items on the scale are summed and range from 0 to 21. Higher scores indicate higher levels of relationship satisfaction. CSI-4 scores falling below 13.5 suggest notable relationship dissatisfaction.
A study staff member administers the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) forms A and B via videoconference (Zoom) . This 30 min validated clinical measure was designed to assess cognitive status in adults and older adults. The five sub-scores include attention, language, visuospatial/construction, immediate and delayed memory as well as a total score. In order to complete this measure via teleconference, couples are mailed the coding subtest in a sealed envelope and told not to open it until the assessment. Then, they are asked to place the completed test in a sealed envelope during the testing session.
Statistical analyses will be conducted using Stata v15 or higher. We will begin with conducting descriptive analyses, including evaluating whether there are any baseline group differences. Any variables that emerge as being significantly different between the two treatment groups will be included as covariates in models predicting outcome variables. If more than three variables emerge as being significantly different between the treatment arms, the full set of demographics and sleep related functioning variables are used to estimate a propensity score indicating likelihood of membership in We-PAP relative to information control (IC); this propensity score is included as a covariate in all tests of study outcomes. Given the pilot nature of the proposed study, significance tests of study hypotheses are performed using one-sided tests with α = 0.10. Feasibility analysis will include review of the adherence and treatment satisfaction measures. Models testing preliminary efficacy will be conducted using multilevel models with separate models will be run for each outcome. The primary outcome is PAP adherence. Secondary outcomes are objective and self-reported sleep quality. Tertiary outcome measures will be explored including relationship satisfaction and cognitive outcomes. Missing data: Mechanisms of missingness will be evaluated in outcomes and potential mediators with missing data. If missingness patterns are consistent with MAR assumptions, recently developed fully conditional specification with chained equations methods for multiple imputation of missing data in MLMs will be used to handle missing data [46, 47]. All variables in hypothesis tests plus additional auxiliary variables will be included; potential auxiliary variables will be carefully screened using methods recommended for small sample sizes . If missingness patterns are consistent with MNAR assumptions, we will consider the use of pattern mixture models  and conditionally dependent dropout  models to minimize any potential bias in estimation of treatment effects.
We selected a sample size of 40 couples (20 per arm) based on power analyses of secondary outcomes with additional consideration of required group sizes for stable and precise estimates of treatment effects and feasibility constraints of the funding mechanism. Although there is some debate about sample size needed to have adequate power for detecting feasibility outcomes , we selected a sample size that will allow us to (1) evaluate the feasibility of enrollment and retention needed to conduct a successful fully powered clinical trial and (2) evaluate preliminary efficacy of our main sleep outcome of interest (PAP use). Power estimates were generated using descriptive statistics for behavioral and cognitive behavioral CPAP interventions vs. IC reported in Wozniak et al. . Power estimates based on these assumptions indicate that a sample size of 20 couples per group provides power of .8 or higher to detect between group differences of d = .68 for average hours of CPAP usage and O.R. = 4.36. Power estimates for patient and partners’ sleep [actigraphy and diary-assessed] were generated using descriptive statistics for behavioral and cognitive behavioral CPAP interventions vs. IC as reported in Wozniak et al.  as well as in Buysse et al.  and Sweetman et al.  Maas and Hox’s (2005)  canonical work on necessary sample sizes for group level effects in MLM determines that group sizes of 20 members and larger is sufficient for generating unbiased estimates for our secondary measures (Table 2).
The We-PAP study is the first intervention designed to improve PAP adherence and overall sleep health for older adult patients with OSA and their partners. This intervention was developed in collaboration with patients, partners, and sleep medicine providers and aims to create a collaborative approach to PAP adherence and sleep health for both the patient and partner. The brief 3-session format and the delivery of the intervention via telehealth is designed to maximize accessibility, by allowing couples to participate from their home at a convenient time.
The significance of this intervention is that We-PAP represents a new conceptual approach to treatment of patients of OSA, by taking a couples-based and transdiagnostic approach to improving sleep health for both the patient and partner. This pilot trial will provide important information regarding the feasibility and acceptability of this intervention. We will recruit equal numbers of male and female patients as well as participants from diverse backgrounds. Even in the first few months, we have been able to enroll couples from rural areas located three or more hours from the clinic, which is important because these patients have greater barriers to attending follow-up visits. We will also be powered to evaluate preliminary efficacy for PAP adherence and improvement in sleep quality.
Limitations to this study include lack of a robust plan for recruiting diverse participants. In a larger, fully powered study, we will plan to recruit from multiple sites, thus increasing the race/ethnic and geographic diversity of our sample. We will also administer our intervention in Spanish, which will extend our intervention to Utah’s largest minority population (> 20% of the population of Salt Lake City). In addition, in larger studies we will have the ability to determine mechanisms of the treatment effect, such as whether changes in relationships or dyadic coping predict changes in adherence.
If successful, our next steps will be to test the We-PAP intervention in a fully powered RCT to evaluate the We-PAP intervention to treatment as usual in a larger and more diverse patient sample. This intervention has the potential to improve aging-related health and cognitive outcomes for older adults. This intervention may also be useful for patients with cognitive difficulties, including mild cognitive impairment (MCI) and Alzheimer’s disease (AD), given that PAP adherence in these populations has the potential to improve cognitive function.
Availability of data and materials
Obstructive Sleep Apnea
Positive Airway Pressure
Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population—a review on the epidemiology of sleep apnea. J Thorac Dis. 2015;7(8):1311.
Fu Y, Xia Y, Yi H, Xu H, Guan J, Yin S. Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea with or without continuous positive airway pressure treatment. Sleep Breath. 2017;21(1):181–9.
Neau JP, Paquereau J, Meurice JC, Chavagnat JJ, Gil R. Stroke and sleep apnoea: cause or consequence? Sleep Med Rev. 2002;6(6):457–69.
Durgan DJ, Bryan RM Jr. Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc. 2012;1(4):e000091.
Lutsey PL, Misialek JR, Mosley TH, et al. Sleep characteristics and risk of dementia and Alzheimer’s disease: The Atherosclerosis Risk in Communities Study. Alzheimers Dement. 2018;14(2):157–66.
da Silva RA. Sleep disturbances and mild cognitive impairment: a review. Sleep Sci. 2015;8(1):36–41.
Andrade AG, Bubu OM, Varga AW, Osorio RS. The relationship between obstructive sleep apnea and Alzheimer’s disease. J Alzheimers Dis. 2018;64(s1):S255–70.
Elias A, Cummins T, Tyrrell R, et al. Risk of Alzheimer’s disease in obstructive sleep apnea syndrome: amyloid-beta and tau imaging. J Alzheimers Dis. 2018;66(2):733–41.
National Sleep Foundation. 2005 Sleep in America Poll. Washington, DC: National Sleep Foundation; 2005.
Luyster FS. Impact of obstructive sleep apnea and its treatments on partners: a literature review. J Clin Sleep Med. 2017;13(3):467–77.
Troxel WM, Robles TF, Hall M, Buysse DJ. Marital quality and the marital bed: examining the covariation between relationship quality and sleep. Sleep Med Rev. 2007;11(5):389–404.
Cartwright RD. Sleeping together: a pilot study of the effects of shared sleeping on adherence to CPAP treatment in obstructive sleep apnea. J Clin Sleep Med. 2008;4(2):123–7.
Beninati W, Harris CD, Herold DL, Shepard JW Jr. The effect of snoring and obstructive sleep apnea on the sleep quality of bed partners. Mayo Clin Proc. 1999;74(10):955–8.
Huang Z, Liu Z, Luo Q, et al. Long-term effects of continuous positive airway pressure on blood pressure and prognosis in hypertensive patients with coronary heart disease and obstructive sleep apnea: a randomized controlled trial. Am J Hypertens. 2015;28(3):300–6.
Weaver TE, Chasens ER. Continuous positive airway pressure treatment for sleep apnea in older adults. Sleep Med Rev. 2007;11(2):99–111.
Troussiere AC, Charley CM, Salleron J, et al. Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2014;85(12):1405–8.
Sawyer AM, Gooneratne NS, Marcus CL, Ofer D, Richards KC, Weaver TE. A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. Sleep Med Rev. 2011;15(6):343–56.
Weaver TE. Adherence to positive airway pressure therapy. Curr Opin Pulm Med. 2006;12(6):409–13.
Budhiraja R, Parthasarathy S, Drake CL, et al. Early CPAP use identifies subsequent adherence to CPAP therapy. Sleep. 2007;30(3):320–4.
Aloia MS, Goodwin MS, Velicer WF, et al. Time series analysis of treatment adherence patterns in individuals with obstructive sleep apnea. Ann Behav Med. 2008;36(1):44–53.
Beninati W, Harris CD, Herold DL, Shepard Jr JW. The effect of snoring and obstructive sleep apnea on the sleep quality of bed partners. In: Mayo Clinic Proceedings. Vol. 74, No. 10. 1999. p. 955–58.
Ye L, Malhotra A, Kayser K, et al. Spousal involvement and CPAP adherence: a dyadic perspective. Sleep Med Rev. 2015;19:67–74.
Martire LM, Schulz R, Helgeson VS, Small BJ, Saghafi EM. Review and meta-analysis of couple-oriented interventions for chronic illness. Ann Behav Med. 2010;40(3):325–42.
Elsevier. Baron KG, Smith TW, Czajkowski LA, Gunn HE, Jones CR. Relationship quality and CPAP adherence in patients with obstructive sleep apnea. Behav Sleep Med. 2009;7(1):22–36.
Luyster FS, Aloia MS, Buysse DJ, Dunbar-Jacob J, Martire LM, Sereika SM, Strollo PJ. A couples-oriented intervention for positive airway pressure therapy adherence: a pilot study of obstructive sleep apnea patients and their partners. Behav Sleep Med. 2018.
Luyster FS, Aloia MS, Buysse DJ, et al. A couples-oriented intervention for positive airway pressure therapy adherence: a pilot study of obstructive sleep apnea patients and their partners. Behav Sleep Med. 2019;17(5):561–72.
Gooneratne NS, Vitiello MV. Sleep in older adults: normative changes, sleep disorders, and treatment options. Clin Geriatr Med. 2014;30(3):591–627.
Troxel WM, Buysse DJ, Matthews KA, et al. Sleep symptoms predict the development of the metabolic syndrome. Sleep. 2010;33(12):1633–40.
Koren D, Dumin M, Gozal D. Role of sleep quality in the metabolic syndrome. Diabetes Metab Syndr Obes. 2016;9:281.
Ballesio A, Aquino MRJV, Kyle SD, Ferlazzo F, Lombardo C. Executive functions in insomnia disorder: A systematic review and exploratory meta-analysis. Front Psychol. 2019;10:101.
Fortier-Brochu É, Beaulieu-Bonneau S, Ivers H, Morin CM. Insomnia and daytime cognitive performance: a meta-analysis. Sleep Med Rev. 2012;16(1):83–94.
Ong JC, Crisostomo MI. The more the merrier? Working towards multidisciplinary management of obstructive sleep apnea and comorbid insomnia. J Clin Psychol. 2013;69(10):1066–77.
Wickwire EM, Smith MT, Birnbaum S, Collop NA. Sleep maintenance insomnia complaints predict poor CPAP adherence: a clinical case series. Sleep Med. 2010;11(8):772–6.
Guilleminault C, Davis K, Huynh NT. Prospective randomized study of patients with insomnia and mild sleep disordered breathing. Sleep. 2008;31(11):1527–33.
Alessi CA, Fung CH, Dzierzewski JM, et al. Randomized controlled trial of an integrated approach to treating insomnia and improving the use of positive airway pressure therapy in veterans with comorbid insomnia disorder and obstructive sleep apnea. Sleep. 2021;44(4):zsaa235.
Harvey AG, Hein K, Dong L, et al. A transdiagnostic sleep and circadian treatment to improve severe mental illness outcomes in a community setting: study protocol for a randomized controlled trial. Trials. 2016;17(1):606.
Butterfield RM, Lewis MA. Health-related social influence: A social ecological perspective on tactic use. J Soc Pers Relat. 2002;19(4):505–26.
Franks MM, Stephens MAP, Rook KS, Franklin BA, Keteyian SJ, Artinian NT. Spouses’ provision of health-related support and control to patients participating in cardiac rehabilitation. J Fam Psychol. 2006;20(2):311–8.
Kiecolt-Glaser JK, Loving TJ, Stowell JR, et al. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005;62(12):1377–84.
Troxel WM, Germain A, Buysse DJ. Clinical management of insomnia with brief behavioral treatment (BBTI). Behav Sleep Med. 2012;10(4):266–79.
Freedland KE, Mohr DC, Davidson KW, Schwartz JE. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med. 2011;73(4):323–35.
Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012;35(2):287–302.
Buysse DJ, Yu L, Moul DE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep. 2010;33(6):781–92.
Funk JL, Rogge RD. Testing the ruler with item response theory: increasing precision of measurement for relationship satisfaction with the Couples Satisfaction Index. J Fam Psychol. 2007;21(4):572.
Randolph C. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). San Antonio: Psychological Corporation; 1998.
Enders CK, Keller BT, Levy R. A fully conditional specification approach to multilevel imputation of categorical and continuous variables. Psychol Methods. 2018;23(2):298–317.
Enders CK. Multiple imputation as a flexible tool for missing data handling in clinical research. Behav Res Ther. 2017;98:4–18.
Hardt J, Herke M, Leonhart R. Auxiliary variables in multiple imputation in regression with missing X: a warning against including too many in small sample research. BMC Med Res Methodol. 2012;12:184.
Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods. 1997;2(1):64.
Little RJ. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc. 1995;90(431):1112–21.
Lewis M, Bromley K, Sutton CJ, McCray G, Myers HL, Lancaster GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Pilot and feasibility studies. 2021;7(1):1–14.
Wozniak DR, Lasserson TJ, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2014;(1).
Germain A, Moul DE, Franzen PL, et al. Effects of a brief behavioral treatment for late-life insomnia: preliminary findings. J Clin Sleep Med. 2006;2(4):403–6.
Sweetman A, Lack L, Catcheside PG, et al. Cognitive and behavioral therapy for insomnia increases the use of continuous positive airway pressure therapy in obstructive sleep apnea participants with comorbid insomnia: a randomized clinical trial. Sleep. 2019;42(12):zsz178.
Maas CJ, Hox JJ. Sufficient sample sizes for multilevel modeling. Methodology. 2005;1(3):86–92.
The We-PAP study began recruiting in May 2021. To date, 32 couples have been enrolled and 26 couples randomized to We-PAP or Information Control.
Ethics approval and consent to participate
This study was approved by the University of Utah Institutional Review Board (IRB_00135927) and all participants provided electronically signed informed consent.
All authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Baron, K.G., Gilles, A., Sundar, K.M. et al. Rationale and study protocol for We-PAP: a randomized pilot/feasibility trial of a couples-based intervention to promote PAP adherence and sleep health compared to an educational control. Pilot Feasibility Stud 8, 171 (2022). https://doi.org/10.1186/s40814-022-01089-x
- Obstructive sleep apnea (OSA)
- Positive airway pressure (PAP)
- Cognitive behavioral
- Alzheimer’s disease